Communication of the meeting of Transparency Council No. 13/2026 on 30 March with resolutions
We invite you to read minutes of the meeting of Transparency Council No. 13/2026 on 30 March 2026 during which the following resolutions were adopted:
- At its meeting on 30 March 2026, the Transparency Council adopted position No. 38/2026 on the evaluation of the drug Skyrizi (risankizumab) under the B.55 drug program. “Treatment of patients with ulcerative colitis (UC) (ICD-10: K51)”
- At its meeting on 30 March 2026, the Transparency Council adopted position No. 39/2026 on the evaluation of the drug Skyrizi (risankizumab) under the B.32 drug program: “Treatment of patients with Crohn’s disease (ICD-10: K50)”
- At its meeting on 30 March 2026, the Transparency Council adopted opinion No. 40/2026 on the appraisal of drug regarding the inclusion of the medicinal product Alhemo (concizumab) in the health policy program “National Program for the Treatment of Patients with Hemophilia and Related Bleeding Disorders for 2024–2028”
- At its meeting on 30 March 2026, the Transparency Council adopted opinion No. 41/2026 on the draft program “REGIONAL HEALTH POLICY PROGRAM – Healthy Aging – Rehabilitation and Spa Treatment for Residents of the Kamień Pomorski Municipality (2025–2029)”